Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Exclusion Criteria

• •Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.
• •Patients whose creatinine clearance is 50mL/min or less at the time of completion of drug administration in the study NCT00330681.
• •Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.
• •Patients who are participating in other clinical trials except the study NCT00330681.